Stocktoria
CorMedix Inc. CRMD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-03-25
CorMedix Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $311.7M | $43.5M | — | $65,408 | $190,936 |
| Gross profit | $275.7M | $40.3M | — | $61,674 | $41,998 |
| R&D expense | $19.3M | $3.9M | $13.2M | $10.7M | $13.1M |
| SG&A expense | — | — | $35.8M | $20.0M | $16.3M |
| Operating income | $150.1M | -$22.4M | -$49.0M | -$30.6M | -$29.4M |
| Interest expense | — | — | $34,296 | $26,515 | $15,943 |
| Income tax | -$13.0M | -$1.4M | — | -$585,617 | -$1.3M |
| Net income | $163.1M | -$17.9M | -$46.3M | -$29.7M | -$28.2M |
| EPS (diluted) | $2.04 | $-0.30 | $-0.91 | $-0.74 | $-0.75 |
| Operating cash flow | $175.0M | -$50.6M | -$38.4M | -$24.4M | -$21.2M |
| Free cash flow | $172.8M | -$50.7M | -$38.7M | -$24.6M | -$22.6M |
| Cash & equivalents | $144.8M | $40.7M | $43.6M | $43.1M | $53.3M |
| Inventory | $29.7M | $7.6M | $2.1M | — | $3,008 |
| Total assets | $826.1M | $118.8M | $82.1M | $62.0M | $68.9M |
| Total liabilities | $420.8M | $34.2M | $11.9M | $7.0M | $6.1M |
| Shareholders' equity | $405.3M | $84.7M | $70.1M | $55.1M | $62.8M |
Source: SEC EDGAR filings · CIK 0001410098 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.